Tuberculosis Therapy
Gatifloxacin shows promise as part of antituberculous regimen
Published in TB and Outbreaks Week, September 23rd, 2003
In a recent study from New York, the use of GAT "in combination with ethionamide (ETA) with or without pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation period was evaluated in a model of tuberculosis in mice."
"Mice treated with GAT at 300 mg/kg of body weight in combination with ETA (25 mg/kg) for five days per week had sterile lungs, whereas mice treated with GAT (100 mg/kg) and ETA (25 mg/kg) had about 10 CFU/lung," reported M.H. Cynamon and coauthors at the Veterans Affairs Medical Center in Syracuse. However, "there was regrowth of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Infectious Disease Therapy
Novel carbapenems show promise for treatment of drug-resistant pathogens - Infectious Disease Therapy
Novel parenteral cephalosporin shows promise against MRSA and other pathogens - Infectious Disease Therapy
Garenoxacin highly active against resistant Streptococcus pneumoniae - Infectious Disease Therapy
Telithromycin highly active against resistant respiratory tract pathogens - Malaria Therapy
Ankyrin peptide blocks falcipain-2-mediated malaria parasite release - Malaria Therapy
Artesunate-primaquine antimalarial regimen highly effective in Thailand - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
